What are the recommended treatment options for non‑small cell lung cancer (NSCLC) with EGFR exon 19 deletions, exon 21 L858R point mutations, and exon 20 insertions?

Treatment of NSCLC with EGFR Exon 19,20, and 21 Mutations

For EGFR exon 19 deletions and exon 21 L858R mutations, osimertinib monotherapy remains the preferred first-line treatment for most patients, while combination regimens (amivantamab-lazertinib or osimertinib plus platinum-pemetrexed) should be reserved for high-risk patients with liver metastases, CNS involvement, high tumor burden, or elevated circulating tumor DNA. For EGFR exon 20 insertions, amivantamab is the standard treatment after platinum-based chemotherapy failure 1.

EGFR Exon 19 Deletions and Exon 21 L858R Mutations

First-Line Treatment Algorithm

Preferred for Standard-Risk Patients:

• Osimertinib 80 mg daily is the standard of care 2, 1, 3
• Appropriate for all performance status levels (0-4) 3
• Particularly beneficial for patients with CNS metastases 2

Alternative Single-Agent Options:

• Erlotinib, gefitinib, afatinib, or dacomitinib are acceptable alternatives 2, 3
• These remain category 1 recommendations but are generally less preferred than osimertinib

Combination Therapy for High-Risk Patients:

The 2024 ASCO guidelines now include combination options with moderate evidence quality 1. Consider these for patients with:

• Liver metastases
• Baseline CNS involvement
• High tumor burden
• Elevated circulating tumor DNA at baseline 4, 5

Two combination regimens are available:

1. Amivantamab-lazertinib 1, 6

   • Improves PFS (HR 0.7) compared to osimertinib alone
   • Grade 3+ adverse events in 75% vs 43% with osimertinib
   • Most common: paronychia and rash
   • 10% discontinuation rate vs 3% with osimertinib
   • Subcutaneous formulation may improve tolerability 4

2. Osimertinib plus platinum-pemetrexed 3

   • Category 1 for nonsquamous histology
   • Median PFS 25.5 vs 16.7 months (HR 0.62)
   • Higher chemotherapy-related toxicity
   • No clear OS benefit demonstrated yet

Critical Decision Point: The lack of clear overall survival benefit and substantially greater toxicity with combination regimens means single-agent osimertinib remains appropriate for most patients 2, 7. Combination therapy should be discussed primarily for biologically high-risk disease 4.

Important Caveat: Avoid initiating osimertinib within 3 months of immune checkpoint inhibitor therapy due to increased pneumonitis risk 3. If EGFR mutation is discovered during first-line immunotherapy, account for the long half-life of ICIs before starting TKI therapy.

Second-Line and Beyond

After First/Second-Generation TKI Progression:

• Test for T790M mutation via plasma cfDNA and/or tissue biopsy 2, 1
• If T790M-positive: Osimertinib (high evidence, strong recommendation) 1, 7
• If T790M-negative: Platinum-based chemotherapy 2, 7

After Osimertinib Progression:

1. Perform NGS testing (tissue or cfDNA) to identify targetable resistance mechanisms 2, 3

2. For symptomatic systemic progression or multiple lesions:

   • Preferred: Amivantamab plus carboplatin-pemetrexed (category 1 for nonsquamous) 1, 3
   • PFS 6.3 vs 4.2 months with chemotherapy alone (HR 0.48)
   • 64% objective response rate vs 36% with chemotherapy
   • Most common grade 3+ events: neutropenia, thrombocytopenia, anemia

3. Alternative: Platinum-based chemotherapy alone 2, 1, 7

   • May add bevacizumab for adenocarcinoma if safe 1

4. Avoid anti-PD-(L)1 agents with or without chemotherapy in this setting (high evidence, strong recommendation against) 1, 3

   • Multiple studies show lack of benefit regardless of PD-L1 expression 3

For Oligoprogression:

• Continue TKI with local ablative therapy (radiation or surgery) to progressing sites 2, 3
• Retrospective data suggest survival benefit with this approach
• Discuss in multidisciplinary tumor board 2

For Slow/Asymptomatic Progression:

• May continue EGFR TKI with ongoing clinical benefit 2

Critical Pitfall: Approximately 5% of EGFR TKI-resistant tumors transform to small cell histology—rebiopsy is strongly recommended before selecting second-line therapy 3.

EGFR Exon 20 Insertions

These represent 4-12% of EGFR mutations and are fundamentally different from classical mutations 8, 9.

Key Characteristics:

• Heterogeneous group with variable TKI sensitivity
• Generally resistant to first-, second-, and third-generation EGFR TKIs 3, 8
• Inferior prognosis compared to classical mutations 8

Treatment Recommendations:

First-Line:

• Platinum-based chemotherapy remains standard 8
• Novel agents are emerging but not yet standard first-line options

Second-Line (After Platinum Chemotherapy):

• Amivantamab (low evidence, strong recommendation) 1, 7, 9
• FDA accelerated approval in May 2021 for this indication
• Bispecific antibody targeting both EGFR and MET
• Represents the only approved targeted therapy for this mutation subtype

Emerging Options:

• Sunvozertinib showing promise in clinical trials 8
• Multiple novel targeted agents in development
• Clinical trial enrollment strongly encouraged 8

Uncommon/Atypical EGFR Mutations (G719X, L861Q, S768I)

These account for approximately 10% of EGFR mutations 2, 3.

Treatment Recommendations:

First-Line Options (in order of preference):

1. Afatinib (low evidence, strong recommendation) 2, 1, 6

   • Only FDA/EMA-approved agent specifically indicated for G719X, S768I, and L861Q
   • Approved in 2018 for these specific variants

2. Osimertinib (low evidence, weak recommendation) 1, 6

   • May be considered as alternative
   • Less robust data than for classical mutations

3. Standard chemotherapy following non-driver alteration guidelines (low evidence, weak recommendation) 1, 6

Important Note: These mutations show distinct response patterns favoring second-generation TKIs like afatinib over third-generation agents in preclinical models 10, 11. The recently proposed PACC (P-loop and αC-helix compressing) classification helps predict TKI sensitivity 10, 11.

Monitoring During Treatment

Initial Therapy:

• CT (with or without contrast) of chest, abdomen, pelvis after 2 cycles
• Then every 2-4 cycles 3

Maintenance/Subsequent Therapy:

• CT every 6-12 weeks 3

Circulating Tumor DNA:

• Emerging as valuable biomarker for real-time monitoring 12
• Can identify treatment failure early and guide therapeutic adjustments
• Dynamics in first days/weeks predict benefit from TKI monotherapy 5

Special Populations

CNS Metastases:

• Osimertinib particularly effective (only 6% CNS progression vs 15% with erlotinib/gefitinib) 3
• Multidisciplinary approach integrating systemic therapy with radiation when needed 12

Poor Performance Status:

• All single-agent EGFR TKIs appropriate for PS 0-4 3
• Combination regimens require careful consideration of toxicity burden

Oligometastatic Disease (3-5 metastases):

• Consider definitive local therapy (SABR or surgery) as consolidation after initiating TKI 3
• May improve outcomes in selected patients